COVID-19 Update:Learn more about how we are protecting our patients, families and staff, as well as other important facts about COVID-19.
Pediatric Plexiform Neurofibromas
Key points about pediatric plexiform neurofibromas:
- Plexiform neurofibromas are a common complication of neurofibromatosis.
- Diagnosed through physical examinations. However, the full extent of the lesion is best seen by MRI scans.
- Approximately 75% of patients who undergo a complete removal of the tumor — without causing significant neurologic impairment or dysfunction — are cured.
Children's National Hospital is a member of the Department of Defense Neurofibromatosis Clinical Trials Consortium — of which Roger Packer, M.D. acts as group chair. Children's National completed a trial evaluating a new biologic agent, Pirfenidone. Through the Department of Defense Consortium, Children's is currently evaluating the efficacy of another biologic agent — Rapamycin — which is designed to inhibit the proliferation of plexiform neurofibromas.
Plexiform neurofibromas are a common complication of neurofibromatosis.
Plexiform neurofibromas are predominantly inherited tumors that can occur anywhere in the body. This includes the head and neck, extremities, areas around the spine and deep in the body where they may affect organs.
Although these tumors tend to grow slowly, they may grow to an enormous size and can cause serious disfigurement, brain dysfunction or impingement on other organs. They may also cause pain.
Until recently, the only known effective treatment for plexiform neurofibromas has been surgery. Approximately 75% of patients who undergo a complete removal of the tumor without causing significant neurologic impairment or dysfunction are cured.
Children's National Hospital and other sites around the country are developing new therapies for patients whose tumors can only be partly removed. Most of these treatments are biologically based and designed to treat the genetic foundations of the tumor.
These types of congenital lesions occur in up to 60% of patients with neurofibromatosis. However, only a minority of these patients is symptomatic and requires treatment.
Although diagnosis of these lesions is usually possible by examination of the child, the full extent of the lesion is best seen by MRI scan. MRI scans may show these lesions to be much more extensive than previously thought. For those patients with tumors around the spine, the lesions may be extremely extensive.
Senior Vice President, Center for Neuroscience and Behavioral Medicine
Director, Gilbert Neurofibromatosis Institute
Director, Brain Tumor Institute
Learn more about our world-renowned Gilbert Family Neurofibromatosis Institute, which helps children with neurofibromatosis type 1 or 2 live more normal lives.
Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you.
Make it happen
Ida Namazi is a bright, ambitious 21-year-old University of Virginia junior who dreams of attending law school and becoming a senator one day. What people might not know about Ida is that she was diagnosed with neurofibromatosis type 1 (NF1) when she was a toddler and has been battling the neurologic condition her whole life.
Read More of Ida's Story